TAKE SURVIVAL FURTHER
TEVIMBRA + zanidatamab-hrii + chemotherapy is the first regimen to surpass 2 years mOS in 1L HER2+ GEA, regardless of PD-L1 status1-4
TEVIMBRA + zanidatamab-hrii + chemotherapy
(n=302)
26.4
months
mOS
mOS
Trastuzumab + chemotherapy
(n=308)
19.2
months
mOS
mOS
HR: 0.72
(95% CI: 0.57-0.90; P=0.004)
TEVIMBRA + chemotherapy
(n=231)
16.8
months
mOS
mOS
Placebo + chemotherapy
(n=250)
9.6
months
mOS
mOS
HR: 0.66
(95% CI: 0.53-0.82)
TEVIMBRA + chemotherapy
(n=432)
15.0
months
mOS
mOS
Placebo + chemotherapy
(n=453)
12.8
months
mOS
mOS
HR: 0.78
(95% CI: 0.67-0.90)
TEVIMBRA + zanidatamab + chemotherapy is the first regimen to surpass 2 years mOS in 1L HER2+ GEA PD-L1 all comers1-4
TEVIMBRA + zanidatamab + chemotherapy is the first regimen to surpass 2 years mOS in 1L HER2+ GEA (PD-L1 all comers)1-4
1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEA, gastroesophageal adenocarcinoma; GEJC, gastroesophageal junction cancer; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mOS, median overall survival; PD-L1, programmed death ligand 1.
References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026. 2. Shitara K, Elimova E, Liu T, et al. N Engl J Med. 2026;394(20):2002-2014. doi:10.1056/NEJMoa2517729 3. Herceptin. Prescribing Information. Genentech, Inc.; 2026. 4. Keytruda. Prescribing Information. Merck & Co. Inc.; 2026.